Market Update Economic Events Directors Deals Commodities Prices News Market Movers

MaxCyte books annual loss owing to R&D, marketing spending

Wednesday, 24th April 2019
Cell-based medicines group MaxCyte booked a full-year loss after rising sales were more than offset by spending, including on R&D and marketing.

Net losses for the year through December amounted to $8.9m, compared to losses of $9.9m on-year.

Revenue rose 19% to $16.7m.

'Our core markets, cell therapy and immuno-oncology, continue to expand rapidly as do applications for gene-editing technologies in the development of various therapies for the treatment of inherited genetic diseases and a number of cancers,' chief executive Doug Doerfler said.

'Our unique technology places MaxCyte at the forefront of a wide variety of programmes with leading global partners across this exciting and increasingly valuable area of healthcare.'

Story provided by

Related Shares: Maxcyte (Di)

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.